This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of amantadine
PDMED_AMANTADINE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
581 |
4. Check minimum number of events
Min. number of events
3
|
581 |
5. Include endpointsNone |
581 |
6. Filter based on genotype QC (FinnGen only) |
581 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of amantadine
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 581 | 381 | 200 |
| Unadjusted period prevalence (%) | 0.12 | 0.13 | 0.09 |
| Median age at first event (years) | 52.33 | 48.28 | 60.03 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 513
- Matched controls
- 5129
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BB01
ATC
amantadine; oral
+∞
323.0
513
28
G35
ICD-10 Finland
Multiple sclerosis
164.4
223.8
224
24
109
Kela drug reimbursment
Multiple sclerosis
175.3
181.5
182
16
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
59.4
164.8
192
51
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
179.8
160.2
161
13
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
46.5
156.3
192
65
G20
ICD-10 Finland
Parkinson disease
46.0
151.9
187
63
N04BD01
ATC
selegiline; oral
97.6
141.2
152
22
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
120.2
113.8
120
13
L03AB07
ATC
interferon beta-1a; parenteral
348.9
112.9
110
*
N86
ICPC
Multiple sclerosis
100.5
108.7
117
15
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
88.7
106.9
117
17
N04BD02
ATC
rasagiline; oral
150.9
94.8
98
8
193
Kela drug reimbursment
Rasagiline
171.6
83.9
86
6
L03AX13
ATC
glatiramer acetate; parenteral
128.8
81.8
86
8
L03AB08
ATC
interferon beta-1b; parenteral
212.1
72.2
73
*
M03BX01
ATC
baclofen; systemic
34.6
66.8
87
30
N04BC04
ATC
ropinirole; oral
47.4
63.5
77
19
N04BC05
ATC
pramipexole; oral
8.8
63.1
149
228
N03AE01
ATC
clonazepam; systemic
11.1
61.9
125
144
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
9.2
57.4
130
183
H46
ICD-10 Finland
Optic neuritis
51.2
56.1
67
15
N87
ICPC
Parkinsonism
32.5
55.4
73
26
N04BX02
ATC
entacapone; oral
150.5
51.9
54
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
53.5
44.8
53
11
G04BD04
ATC
oxybutynin; oral, transdermal
8.0
42.9
104
158
N06BA07
ATC
modafinil; oral
98.5
41.5
45
5
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
429.6
40.7
40
*
N03AX12
ATC
gabapentin; oral
4.5
39.2
164
483
G04BD09
ATC
trospium; oral
14.1
39.0
68
55
164
Kela drug reimbursment
Fingolimod
89.0
37.4
41
5
G04BD12
ATC
mirabegron; oral
5.2
35.9
125
301
L04AA31
ATC
teriflunomide; oral
82.0
34.3
38
5
N04BC09
ATC
rotigotine; transdermal
99.5
34.2
37
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
11.3
33.7
65
65
L04AA27
ATC
fingolimod; oral
79.3
33.3
37
5
XA800
NOMESCO Finland
Neuropsychological investigation
10.2
30.6
62
68
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
17.5
30.5
48
30
353
Kela drug reimbursment
Cladribine and fingolimod
88.1
30.1
33
*
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
308.5
29.1
29
*
N04BC02
ATC
pergolide; oral
296.8
28.0
28
*
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
37.4
27.8
35
10
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
+∞
27.3
26
*
N06AB04
ATC
citalopram; systemic
3.2
26.9
177
725
J01EA01
ATC
trimethoprim; systemic
2.9
25.7
203
936
G04BD07
ATC
tolterodine; oral
5.7
24.9
75
149
SPAT1229
SPAT
Assessment of need for aid
4.5
24.0
92
238
UKC02
NOMESCO Finland
Cystoscopy
3.4
23.2
127
447
L04AX07
ATC
dimethyl fumarate; oral
54.6
22.3
26
5
G04BD08
ATC
solifenacin; oral
4.9
21.0
72
165
XKC03
NOMESCO Finland
Water cystometry
7.5
20.8
50
73
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.7
20.7
74
177
TAB00
NOMESCO Finland
Lumbar puncture
6.6
20.2
53
88
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.0
19.4
55
101
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.1
18.5
42
56
N05CF01
ATC
zopiclone; oral
2.4
18.3
215
1188
XKD00
NOMESCO Finland
Uroflowmetry
3.2
18.2
109
404
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
23.8
17.9
25
11
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
17.8
17
*
A06AD11
ATC
lactulose; oral
3.0
17.8
118
468
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
43.6
17.4
21
5
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.0
17.3
112
437
N07XX09
ATC
[U] dimethyl fumarate; oral
51.9
17.1
20
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
18.2
17.1
26
15
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
16.8
132
578
R35
ICD-10 Finland
Polyuria
4.3
16.6
63
160
N04AA02
ATC
biperiden; systemic
8.9
16.5
35
42
N06AX11
ATC
mirtazapine; oral
2.3
16.4
200
1108
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.4
16.1
60
149
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
21.8
16.1
23
11
R33
ICD-10 Finland
Retention of urine
4.0
16.0
67
186
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.8
15.7
111
456
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
164.8
15.6
16
*
G02CB01
ATC
bromocriptine; systemic
9.6
15.4
31
34
L28
ICPC
Limited function/disability (L)
2.7
14.9
119
522
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
14.6
164
863
N05BA01
ATC
diazepam; systemic, rectal
2.8
14.5
101
409
XKD03
NOMESCO Finland
Urethral pressure profilometry
7.4
14.4
34
49
SPAT1216
SPAT
Assessment of functional ability
2.7
14.3
111
480
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.4
14.2
71
229
N06AA09
ATC
amitriptyline; systemic
3.0
14.1
87
324
2AB04
NOMESCO Finland
NA
54.9
13.9
16
*
SPAT1231
SPAT
Assessment of adjustments needed in living environment
8.3
13.8
30
38
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
13.5
176
988
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
26.6
13.4
18
7
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
3.5
13.4
64
199
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
10.9
13.4
25
24
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.6
13.3
62
189
XCK00
NOMESCO Finland
Perimetry
3.8
13.3
57
162
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
41.2
13.2
16
*
N05AH04
ATC
quetiapine; oral
2.6
13.2
105
460
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.1
13.0
181
1040
J01CA08
ATC
pivmecillinam; oral
2.0
13.0
244
1590
R1250
NOMESCO Finland
Evaluation of functional capability
8.6
12.7
27
33
N03AX16
ATC
pregabalin; oral
2.2
12.6
160
880
N04BC01
ATC
bromocriptine; oral
+∞
12.5
12
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
10.0
12.4
24
25
N06AX16
ATC
venlafaxine; oral
2.6
12.2
96
416
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
27.4
12.1
16
6
N28
ICPC
Limited function/disability (N)
8.2
12.0
26
33
R25.1
ICD-10 Finland
Tremor, unspecified
6.0
11.8
32
56
N30.0
ICD-10 Finland
Acute cystitis
2.6
11.8
96
422
J01MA02
ATC
ciprofloxacin; systemic
2.0
11.7
221
1422
N03AF01
ATC
carbamazepine; oral, rectal
4.1
11.7
46
121
N04BC06
ATC
cabergoline; oral (dopamine agonists)
30.8
11.7
15
5
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.0
11.6
71
263
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.3
11.5
30
50
N04BX01
ATC
tolcapone; oral
+∞
11.5
11
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
11.5
11
*
A28
ICPC
Limited function/disability NOS
2.4
11.3
101
467
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.3
10.8
55
180
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
18.3
10.8
16
9
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.0
10.6
152
874
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.0
10.6
42
112
G04BD11
ATC
fesoterodine; oral
4.6
10.5
36
83
C07AA05
ATC
propranolol; systemic
2.2
10.5
119
615
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
10.4
10
*
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
19.3
10.3
15
8
N29
ICPC
Neurological sympt/complt other
6.1
10.3
27
46
M03BX02
ATC
tizanidine; oral
1.9
10.2
320
2424
J01XX05
ATC
methenamine; oral
9.4
10.1
20
22
N06DA03
ATC
rivastigmine; oral, transdermal
4.4
10.1
36
87
359
Kela drug reimbursment
Mirabegroni
15.0
10.1
16
11
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.6
10.0
73
303
J01MA06
ATC
norfloxacin; oral
2.3
9.8
96
464
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
56.1
9.7
11
*
N30.9
ICD-10 Finland
Cystitis, unspecified
3.3
9.5
48
156
TKC20
NOMESCO Finland
Catheterisation of bladder
3.0
9.5
54
191
H02AB07
ATC
prednisone; oral
2.3
9.5
94
455
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
17.9
9.4
14
8
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
30.6
9.4
12
*
N04BC07
ATC
apomorphine; parenteral
+∞
9.4
9
*
N05CD07
ATC
temazepam; oral
2.3
9.4
89
422
H02AA02
ATC
fludrocortisone; oral
10.9
9.3
17
16
N06AX18
ATC
reboxetine; oral
8.0
9.2
20
26
U04
ICPC
Incontinence urine
3.7
9.2
40
116
H02AB04
ATC
methylprednisolone; systemic
2.2
9.1
98
494
N06AB10
ATC
escitalopram; oral
2.1
9.0
108
570
34099
ICD-8 Finland
Multiple sclerosis
37.4
9.0
11
*
H47.2
ICD-10 Finland
Optic atrophy
37.4
9.0
11
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.3
8.9
86
410
AA1AD
NOMESCO Finland
CT of head and brain
2.0
8.9
138
810
J01MA01
ATC
ofloxacin; systemic
2.7
8.7
61
244
K59.0
ICD-10 Finland
Constipation
3.2
8.7
45
150
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
8.6
82
391
D21
ICPC
Swallowing problem
7.5
8.5
19
26
Z43.5
ICD-10 Finland
Attention to cystostomy
28.0
8.5
11
*
SPAT1262
SPAT
Handing over of treatment supplies
2.1
8.5
100
524
Z93.5
ICD-10 Finland
Cystostomy status
91.5
8.4
9
*
N05BA04
ATC
oxazepam; oral
1.9
8.3
142
861
R1260
NOMESCO Finland
Evaluation of communicative skills
7.0
8.1
19
28
G04BDXX
ATC
NA
17.5
8.1
12
7
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.5
8.0
63
269
S72.0
ICD-10 Finland
Fracture of neck of femur
3.7
8.0
34
97
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.9
8.0
47
171
N06AX21
ATC
duloxetine; oral
2.4
8.0
68
303
S97
ICPC
Chronic ulcer skin
3.3
8.0
39
125
G04AC01
ATC
NA
4.0
7.9
30
78
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
8.7
7.9
16
19
H53.2
ICD-10 Finland
Diplopia
4.4
7.8
27
64
R01BA52
ATC
pseudoephedrine, combinations; oral
1.8
7.7
168
1100
ZX120
NOMESCO Finland
Intravenous
2.5
7.7
61
264
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
6.9
7.6
18
27
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
18.7
7.6
11
6
N03AF02
ATC
oxcarbazepine; oral
4.3
7.6
27
66
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.7
7.6
49
190
U02
ICPC
Urinary frequency/urgency
2.2
7.5
79
392
ABD99
NOMESCO Finland
Other operation on spinal cord or nerve for pain or impaired function
81.2
7.4
8
*
R03CA02
ATC
ephedrine; oral
81.2
7.4
8
*
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
13.6
7.4
12
9
G04BD01
ATC
emepronium; systemic
8.5
7.4
15
18
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
7.0
7.3
17
25
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
4.8
7.3
23
50
L04AX01
ATC
azathioprine; systemic
3.7
7.2
30
85
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.3
7.2
64
295
M01AG02
ATC
tolfenamic acid; oral, rectal
2.0
7.1
91
492
G04CA02
ATC
tamsulosin; oral
2.0
6.9
100
566
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.3
6.9
64
299
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
40.6
6.8
8
*
G04BD
ATC
Drugs for urinary frequency and incontinence
17.0
6.8
10
6
4AA23
NOMESCO Finland
NA
22.8
6.7
9
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.7
6.7
21
46
R4130
NOMESCO Finland
Speech therapy
5.2
6.6
19
38
N02AX02
ATC
tramadol; systemic, rectal
1.6
6.5
213
1552
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.9
6.5
38
139
R5110
SPAT
NA
4.2
6.5
23
57
N03AX09
ATC
lamotrigine; oral
3.3
6.5
31
99
N07AA03
ATC
distigmine; systemic
14.5
6.4
10
7
M41.9
ICD-10 Finland
Scoliosis, unspecified
6.7
6.4
15
23
N05BA12
ATC
alprazolam; oral
2.2
6.3
63
306
A02BA02
ATC
ranitidine; systemic
1.8
6.3
115
703
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
18.3
6.3
9
5
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
+∞
6.3
6
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.0
6.2
84
465
N05CF02
ATC
zolpidem; oral
1.9
6.2
101
597
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
8.7
6.1
12
14
J01XE01
ATC
nitrofurantoin; oral
4.1
6.1
22
56
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
20
16
12.91
20.41
1.7
1.0
59.00
108.32
nmol/l
—
11
10
243
1408
2.25
19.39
5.5
3.1
43.05
57.47
e6/l
0.24
199
1077
23
5
47.75
19.32
2.0
3.6
—
—
—
0
0
274
1671
2.21
19.22
5.4
3.1
—
—
—
0
0
333
2199
2.20
19.05
10.3
5.6
26.68
27.67
%
0.88
313
2048
330
2175
2.20
18.93
9.8
5.3
59.25
57.41
%
1.93
311
2034
326
2144
2.19
18.73
10.3
5.5
2.88
2.80
%
0.27
303
1993
29
46
6.58
17.71
1.2
1.2
—
—
—
0
0
222
1283
2.18
17.42
5.0
3.0
0.26
0.44
e6/l
1.13
180
959
181
975
2.24
16.81
4.4
2.5
4.62
6.15
e6/l
0.83
157
861
264
1650
2.10
16.73
6.3
3.6
103.97
77.25
e6/l
0.30
210
1170
21
29
7.48
14.48
2.4
1.8
14.55
11.53
%
0.40
11
15
35
80
4.59
14.45
3.8
3.2
3.95
4.65
e9/l
0.88
35
80
21
31
6.99
13.66
5.4
1.8
954.27
729.08
e6/l
0.59
11
12
35
85
4.32
13.40
3.9
3.6
59.71
59.54
%
0.02
35
85
360
2655
1.94
13.01
10.9
8.8
4.05
4.11
e9/l
0.21
332
2334
323
2326
1.88
12.27
6.4
3.7
0.00
0.01
estimate
0.50
64
407
319
2294
1.87
12.11
6.3
3.7
0.00
0.00
estimate
0.00
66
423
134
724
2.11
11.85
4.4
2.8
3.96
2.58
e6/l
0.65
79
392
317
2302
1.83
11.40
8.8
5.0
0.00
0.00
estimate
0.50
68
423
395
3071
1.89
11.39
9.7
4.6
516.89
2634.50
e6/l
—
9
58
280
1976
1.80
10.90
2.4
2.2
93.74
77.97
nmol/l
10.44
246
1766
135
775
1.97
9.94
4.2
2.6
1.20
1.11
e6/l
0.17
82
444
26
67
4.02
9.23
2.1
2.4
106.73
105.88
mmol/l
0.31
26
67
26
67
4.02
9.23
2.1
2.4
4.06
4.03
mmol/l
0.14
26
67
11
12
9.32
9.00
8.2
1.3
—
—
—
0
0
16
29
5.65
8.54
2.4
1.8
—
—
—
0
0
122
718
1.88
8.21
1.8
1.9
—
—
—
0
0
10
12
8.46
7.60
1.2
1.0
2060.80
1601.92
miu/ml
—
10
12
10
6
16.93
6.76
1.2
1.0
—
—
—
0
0
15
33
4.64
6.49
1.1
1.0
—
—
—
0
0
241
1808
1.57
6.37
7.2
3.8
—
—
—
0
0
388
4434
0.62
6.33
3.9
3.9
1.24
1.28
mmol/l
0.45
338
4060
16
38
4.30
6.32
1.0
1.1
47.00
41.24
mg/l
—
8
32
406
4587
0.62
6.22
4.3
4.4
1.51
1.50
mmol/l
0.09
351
4222
293
2311
1.54
6.10
6.3
6.1
1.22
1.22
mmol/l
0.06
241
1950
422
4710
0.62
5.84
4.5
5.0
2.70
2.79
mmol/l
1.04
367
4333
195
1426
1.55
5.61
2.5
2.0
161.39
186.25
u/l
0.37
184
1338
412
4612
0.63
5.57
4.2
4.4
4.64
4.73
mmol/l
0.91
357
4262
133
892
1.64
5.50
1.8
1.7
994.85
1217.74
nmol/l
2.12
96
653
329
2699
1.50
5.45
5.7
4.4
6.40
6.69
mmol/l
2.10
317
2527
32
131
2.53
5.38
1.6
1.6
70.09
0.14
iu/ml
—
5
24
246
1906
1.50
5.36
2.3
2.0
92.55
96.06
pmol/l
0.56
135
957
26
100
2.67
4.96
2.8
1.9
2315.57
1117.87
u/l
—
9
33
52
280
1.94
4.54
1.4
1.4
—
—
—
0
0
262
2107
1.44
4.49
6.6
5.4
1.22
1.22
mmol/l
0.04
239
1910
151
1089
1.52
4.49
1.8
1.5
21.90
21.06
nmol/l
0.26
122
918
411
3609
1.47
4.30
7.0
7.2
81.73
78.76
u/l
0.53
379
3376
50
272
1.92
4.24
1.7
1.8
—
—
—
0
0
37
181
2.12
4.20
1.9
1.8
—
—
—
0
0
47
252
1.94
4.16
5.0
2.9
0.11
0.16
e6/l
0.42
47
246
79
497
1.68
4.15
1.6
1.9
—
—
—
0
0
35
169
2.14
4.11
1.7
1.6
—
—
—
0
0
10
24
4.22
3.90
2.8
2.2
—
—
—
0
0
16
406
0.38
3.89
1.9
1.7
—
—
—
0
0
295
2471
1.39
3.81
4.8
5.9
9.53
10.95
umol/l
2.80
275
2344
78
504
1.63
3.70
1.6
1.9
—
—
—
0
0
24
104
2.36
3.64
1.2
1.2
97.06
158.80
e6/l
0.33
17
79
24
104
2.36
3.64
1.0
1.2
5.94
13.40
e6/l
0.49
17
77
7
9
7.86
3.56
1.6
2.0
14.06
18.81
umol/l
—
7
9
16
57
2.86
3.55
1.0
1.1
—
—
—
0
0
16
58
2.81
3.44
1.0
1.1
—
—
—
0
0
259
2148
1.37
3.44
3.9
3.9
—
—
—
0
0
242
2003
1.36
3.19
3.6
4.2
35.27
35.57
g/l
0.35
215
1857
38
211
1.86
3.08
9.4
2.2
0.74
0.66
%
0.97
38
206
143
1094
1.41
3.03
2.2
2.2
—
—
—
0
0
71
473
1.57
2.99
5.1
3.4
—
—
—
0
0
13
47
2.81
2.83
1.0
1.0
—
—
—
0
0
159
1254
1.37
2.79
7.7
4.0
0.00
0.00
estimate
0.50
63
413
219
1827
1.32
2.61
4.8
3.7
32.65
54.74
ng/l
0.56
174
1295
7
17
4.15
2.36
2.0
1.8
67.20
61.82
ug/l
—
7
17
21
391
0.52
2.33
2.1
2.7
62.00
65.35
ml/min/173m2
—
6
173
58
398
1.51
2.18
8.2
2.9
2.54
2.20
mmol/l
0.39
46
314
182
1512
1.30
2.17
3.6
3.0
28.64
30.46
u/l
0.45
173
1434
56
383
1.51
2.14
3.2
3.7
1.22
1.23
mmol/l
0.27
48
336
22
117
1.91
2.09
1.3
1.7
3.84
5.70
iu/l
—
5
38
18
89
2.06
2.08
1.8
2.5
27.08
32.73
umol/l
1.17
13
74
382
3492
1.27
2.04
3.8
4.1
11.07
12.27
mm/h
1.08
339
3205
11
44
2.53
2.02
2.1
2.3
—
—
—
0
0
55
771
0.68
1.96
1.8
1.4
—
—
—
0
0
11
240
0.45
1.95
1.1
1.3
—
—
—
0
0
490
4640
1.36
1.94
19.6
14.0
25.67
22.89
mg/l
0.90
405
3653
84
633
1.38
1.94
1.7
2.1
2.42
2.34
g/l
0.60
72
580
7
22
3.21
1.88
1.1
1.4
—
—
—
0
0
18
93
1.97
1.87
1.2
1.4
—
—
—
0
0
18
93
1.97
1.87
1.2
1.4
—
—
—
0
0
5
12
4.19
1.82
1.2
1.7
—
—
—
0
0
20
110
1.85
1.75
1.6
1.7
—
—
—
0
0
21
119
1.79
1.68
2.2
1.5
—
—
—
0
0
112
1371
0.77
1.67
3.2
3.0
8.16
7.16
mmol/l
1.18
89
1126
90
703
1.33
1.67
1.8
2.2
11.76
12.93
umol/l
0.84
77
642
502
4803
1.33
1.59
21.1
16.0
3.92
3.97
mmol/l
5.08
490
4660
49
670
0.71
1.54
3.2
2.9
0.72
0.78
ug/l
0.25
32
440
162
1379
1.24
1.53
2.5
3.1
1128.29
1313.34
ng/l
0.35
141
1164
454
4294
1.26
1.53
5.5
4.8
1.81
2.20
mu/l
0.74
420
3911
500
4787
1.32
1.52
21.3
15.9
139.91
139.69
mmol/l
1.10
492
4652
122
1009
1.26
1.48
1.3
1.2
0.63
1.75
u/ml
1.59
23
267
71
908
0.75
1.46
4.2
4.3
21.69
21.22
%
0.11
34
424
15
80
1.90
1.46
1.4
1.3
—
—
—
0
0
19
110
1.75
1.44
4.6
2.5
8.36
8.01
kpa
0.46
19
100
43
305
1.44
1.43
1.4
1.3
—
38.90
—
0
22
16
88
1.84
1.42
1.8
1.6
—
—
—
0
0
18
103
1.77
1.42
1.2
1.2
—
—
—
0
0
76
595
1.32
1.40
1.8
2.2
19.52
22.33
%
1.05
64
513
0
37
0.00
1.35
0.0
1.1
—
—
—
0
0
433
4544
0.82
1.33
4.3
4.6
5.72
5.92
mmol/l
4.01
386
4139
6
24
2.52
1.30
1.5
2.0
—
—
—
0
0
68
853
0.77
1.23
1.5
1.3
13.61
35.28
iu/ml
4.52
11
275
120
1013
1.23
1.22
1.8
1.7
423.40
21942891.11
pmol/l
1.06
98
834
5
19
2.65
1.22
1.0
1.1
—
—
—
0
0
8
37
2.18
1.22
1.4
1.8
—
—
—
0
0
0
33
0.00
1.16
0.0
2.6
—
—
—
0
0
133
1141
1.21
1.16
2.6
2.1
3.65
3.18
mg/l
0.81
112
971
37
502
0.72
1.14
3.7
3.9
3.35
30.62
ug/l
1.05
31
414
385
3629
1.18
1.11
4.6
4.0
15.16
14.72
pmol/l
2.43
346
3299
7
31
2.27
1.10
1.1
1.5
3.14
3.13
u/field
—
7
23
15
89
1.70
1.08
3.5
2.4
15.91
16.01
%
—
9
44
69
555
1.28
1.07
3.7
4.5
1.02
1.02
mmol/l
0.00
59
497
166
1466
1.19
1.06
2.3
2.3
51.30
56.11
u/l
1.29
150
1356
94
787
1.23
1.04
1.5
1.4
—
—
—
0
0
5
22
2.28
1.03
1.2
1.3
—
—
—
0
0
5
22
2.28
1.03
1.6
2.0
—
—
—
0
0
329
3075
1.16
1.01
3.7
3.0
48.14
46.75
u/l
0.08
292
2874
12
68
1.78
1.01
1.3
1.7
—
—
—
0
0
405
3848
1.17
1.00
24.2
16.9
13.62
13.72
%
0.86
397
3776
415
4336
0.85
0.99
5.4
5.7
38.98
39.84
mmol/mol
1.18
367
4023
5
23
2.18
0.98
1.6
2.0
—
—
—
0
0
54
427
1.29
0.97
1.9
2.3
28.53
30.84
u/l
0.37
45
358
108
1249
0.83
0.94
1.6
1.6
1.41
1.36
mmol/l
0.21
79
1045
457
4394
1.19
0.94
17.3
12.9
85.26
79.66
ml/min/173m2
7.59
409
3606
21
143
1.49
0.91
1.5
1.6
—
—
—
0
0
42
327
1.31
0.86
2.0
1.5
—
—
—
0
0
70
583
1.23
0.84
4.1
4.5
31.72
32.09
%
0.09
46
387
219
2011
1.14
0.82
2.6
2.7
125.58
113.32
ug/l
0.38
198
1851
9
148
0.60
0.80
1.1
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.2
—
—
—
0
0
116
1022
1.17
0.77
6.2
4.0
1.02
1.02
kg/l
0.14
26
122
8
134
0.59
0.74
1.5
1.3
—
—
—
0
0
102
895
1.17
0.72
2.5
2.7
2.46
2.45
mmol/l
0.27
89
780
5
26
1.93
0.70
1.8
1.7
—
—
—
0
0
5
26
1.93
0.70
1.8
1.7
—
—
—
0
0
69
807
0.84
0.70
1.4
1.3
1.04
10.12
u/ml
3.99
19
322
297
2805
1.12
0.68
3.0
3.0
—
—
—
0
0
9
59
1.53
0.68
1.3
1.8
—
—
—
0
0
124
1380
0.87
0.68
4.1
3.9
3.97
7.21
mg/mmol
1.82
83
840
16
111
1.45
0.66
1.3
1.3
—
—
—
0
0
55
460
1.22
0.66
2.4
1.8
339.98
377.22
nmol/l
0.79
49
418
103
1159
0.86
0.66
1.9
2.5
311.47
7322.55
umol/l
5.04
86
991
8
129
0.61
0.64
5.0
2.1
102.25
92.13
%
—
8
123
29
366
0.78
0.61
1.8
1.8
—
—
—
0
0
17
122
1.41
0.60
3.8
2.6
25.98
24.90
mmol/l
0.67
17
105
0
20
0.00
0.60
0.0
3.7
—
203.25
—
0
20
0
23
0.00
0.58
0.0
1.3
—
—
—
0
0
8
54
1.49
0.57
1.4
1.7
—
—
—
0
0
12
81
1.49
0.57
1.3
1.6
—
—
—
0
0
10
148
0.67
0.55
1.1
1.1
—
—
—
0
0
16
116
1.39
0.55
1.3
1.7
—
—
—
0
0
9
63
1.44
0.52
1.3
1.7
—
—
—
0
0
18
136
1.33
0.49
1.4
1.3
317.57
306.25
ug/g
0.08
12
78
7
46
1.53
0.48
1.3
1.4
19.88
17.24
ug/l
—
7
46
175
1634
1.10
0.48
2.5
3.2
2.35
2.36
mmol/l
0.63
144
1425
18
137
1.32
0.48
1.3
1.2
—
—
—
0
0
23
183
1.27
0.45
1.6
1.7
—
—
—
0
0
27
329
0.81
0.45
1.7
1.7
—
—
—
0
0
16
122
1.32
0.42
1.3
1.7
—
—
—
0
0
23
187
1.24
0.39
1.5
2.0
1.37
1.54
g/l
0.51
18
161
57
507
1.14
0.37
4.8
6.8
0.32
1.55
mmol/l
1.22
45
405
9
70
1.29
0.36
1.3
1.6
—
—
—
0
0
10
134
0.74
0.35
3.1
3.5
—
2.34
—
0
15
15
187
0.80
0.32
1.6
2.0
1.45
3.47
mg/l
—
10
139
12
154
0.77
0.32
2.3
3.0
—
—
—
0
0
413
4214
0.93
0.31
21.9
14.7
38.17
39.62
%
1.67
249
3032
45
502
0.89
0.29
1.5
1.7
1.45
1.45
%
0.00
39
434
17
139
1.23
0.29
1.6
1.7
—
—
—
0
0
12
94
1.28
0.28
1.8
1.5
—
—
—
0
0
8
62
1.29
0.28
1.1
1.1
—
—
—
0
0
8
63
1.27
0.28
3.0
3.1
22.21
64.62
u/ml
—
8
63
8
63
1.27
0.28
1.1
1.4
—
—
—
0
0
8
64
1.25
0.27
1.1
1.4
—
—
—
0
0
8
64
1.25
0.27
1.1
1.4
—
—
—
0
0
8
64
1.25
0.27
1.1
1.4
—
—
—
0
0
8
64
1.25
0.27
1.1
1.4
—
—
—
0
0
8
65
1.23
0.27
1.1
1.4
—
—
—
0
0
11
86
1.28
0.26
1.4
1.7
—
—
—
0
0
20
169
1.19
0.26
1.6
2.0
—
—
—
0
0
9
72
1.25
0.25
1.0
1.2
—
—
—
0
0
36
400
0.89
0.23
2.0
2.5
4.88
7.06
ug/l
0.79
28
354
92
867
1.07
0.22
4.7
3.8
122.80
323.81
ng/l
1.14
71
668
5
41
1.22
0.22
1.0
1.5
—
275.00
—
0
6
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
2.78
—
0
5
0
12
0.00
0.21
0.0
1.6
—
1.25
—
0
12
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
8
104
0.77
0.21
1.3
1.4
—
—
—
0
0
14
117
1.20
0.20
1.8
2.3
0.00
0.00
g/l
0.00
14
110
0
14
0.00
0.20
0.0
1.0
—
24.63
—
0
14
6
49
1.23
0.20
1.0
1.1
1.32
1.50
g/l
—
6
42
109
1142
0.94
0.19
4.9
4.9
2.54
2.53
ug/l
0.01
94
1012
14
119
1.18
0.18
1.8
2.3
0.00
0.00
g/l
0.00
14
111
11
131
0.84
0.17
2.4
2.3
12.99
11.88
mg/l
0.13
11
119
43
399
1.08
0.16
11.1
6.0
1.35
1.35
mmol/l
0.01
43
378
13
111
1.18
0.16
1.1
1.4
—
—
—
0
0
56
528
1.07
0.15
2.1
2.4
8.98
7.55
umol/l
0.28
47
459
18
160
1.13
0.14
1.5
1.4
—
—
—
0
0
78
745
1.05
0.14
2.8
3.1
0.83
0.81
mmol/l
0.60
70
691
15
170
0.88
0.14
1.6
1.9
—
—
—
0
0
40
374
1.07
0.13
2.0
2.5
66.35
67.07
g/l
0.37
31
340
19
211
0.90
0.13
1.1
1.0
—
—
—
0
0
13
114
1.14
0.12
1.3
1.1
—
—
—
0
0
497
4939
1.04
0.11
13.6
10.2
22.63
24.92
u/l
3.02
468
4766
5
44
1.14
0.10
1.0
1.2
—
70.43
—
0
7
13
145
0.89
0.09
1.5
1.2
—
18.30
—
0
10
6
57
1.05
0.08
3.8
3.9
—
—
—
0
0
6
58
1.03
0.08
1.2
1.3
—
—
—
0
0
5
65
0.77
0.08
1.2
1.1
—
—
—
0
0
14
127
1.10
0.08
1.8
2.3
0.00
0.04
g/l
0.50
14
119
12
133
0.90
0.07
1.2
1.2
—
2.78
—
0
18
6
71
0.84
0.07
1.7
1.5
—
—
—
0
0
512
5141
0.97
0.07
30.1
20.6
133.03
134.08
g/l
0.90
507
5056
512
5139
0.97
0.06
29.9
20.5
4.40
4.45
e12/l
1.51
500
4993
512
5137
0.97
0.05
29.9
20.5
260.97
252.19
e9/l
2.46
503
5010
12
111
1.08
0.04
1.2
1.4
—
—
—
0
0
106
1045
1.02
0.04
2.1
1.7
1.31
1.15
mg/l
0.26
88
823
37
359
1.03
0.03
3.8
3.1
66.36
75.00
ng/l
0.78
25
314
10
108
0.92
0.03
1.7
4.1
33.40
29.06
mg/l
—
5
63
59
597
0.99
0.01
14.0
21.6
1.32
1.23
inr
—
5
72
14
134
1.05
0.00
1.6
1.7
—
—
—
0
0
17
165
1.03
0.00
1.4
1.4
—
—
—
0
0
11
107
1.03
0.00
1.1
1.2
—
1.02
—
0
8
33
335
0.98
0.00
1.3
1.2
67.42
165.76
iu/ml
2.63
12
140
11
112
0.98
0.00
1.1
1.2
—
—
—
0
0
58
582
1.00
0.00
5.7
6.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
7
71
0.99
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
1.2
1.7
—
—
—
0
0
5
58
0.86
0.00
1.2
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_AMANTADINE – Use of amantadine
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).